促销时间表 Adynxx Inc
先进的时间表
简单图表
关于公司
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
| ISIN |
US00784D1037 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.adynxx.com
|
| 每日价格变化: |
0% (0.0001) |
| 每周价格变化: |
0% (0.0001) |
| 每月价格变化: |
0% (0.0001) |
| 3个月内价格变化: |
0% (0.0001) |
| 六个月内的价格变化: |
0% (0.0001) |
| 每年价格变化: |
0% (0.0001) |
| 3年内价格变化: |
-99.76% (0.0411) |
| 5年内价格变化: |
-100% (2.48) |
| 10年价格变化: |
0% (0.0001) |
| 年初以来价格变化: |
0% (0.0001) |
|
|
低估
| 姓名 |
意义 |
年级 |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
0 |
0 |
| 全部的: |
|
2.5 |
|
效率
| 姓名 |
意义 |
年级 |
| ROA, % |
0 |
0 |
| ROE, % |
0 |
0 |
| 全部的: |
|
0 |
|
|
|
股息
| 姓名 |
意义 |
年级 |
| Div yield, % |
0 |
0 |
| DSI |
0.5 |
5 |
| 全部的: |
|
2.35 |
|
责任
| 姓名 |
意义 |
年级 |
| Debt/EBITDA |
0 |
10 |
| 全部的: |
|
10 |
|
成长冲动
| 姓名 |
意义 |
年级 |
| 盈利能力 Revenue, % |
-53.7 |
0 |
| 盈利能力 Ebitda, % |
-93.16 |
0 |
| 盈利能力 EPS, % |
-95.64 |
0 |
| 全部的: |
|
0 |
|
| 导师 |
职称 |
支付 |
出生年份 |
| Mr. Richard Orr Esq., J.D. |
President, CEO, Principal Financial Officer & Director |
|
1961 (64 年) |
| Dr. Julien Mamet Ph.D. |
Founder, Chief Scientific Officer & Director |
|
1976 (49 年) |
| Mr. William Martin |
Executive Vice President of Corporate Development & Operations |
|
|
| Ms. Dina Gonzalez |
Principal Accounting Officer & Senior VP of Finance |
|
|
| Ms. Kimberley Hebert |
Senior Director of Clinical Operations |
|
|
